

Drug Monograph

Drug/Drug **Delzicol[®] (mesalamine) delayed release capsule/ Oral**
Class: **Ulcerative Colitis Agents**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Delzicol[®] is available in delayed release capsule. Each capsule contains four 100 mg mesalamine coated tablets.

Manufacturer: Allergan USA, Inc., Irvine, CA 92612

Indications: Delzicol[®] is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. It is also indicated for the maintenance of remission of ulcerative colitis in adults.

Costs: \$2.96 per capsule of Delzicol[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 29, 2016